Abiopharma

ONKURE THERAPEUTICS, INC. (OKUR)

Symbol	OKUR
Name	ONKURE THERAPEUTICS, INC.
Sector	HEALTH CARE
Region	North America
Industry	Biotechnology: Pharmaceutical Preparations
Address	18575 JAMBOREE ROAD,SUITE 275-S, IRVINE, California, 92612, United States
Telephone	+1 619 733-3852
Fax	—
Email	—
Website	https://www.onkuretherapeutics.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001637715
Description	OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene. Additional info from NASDAQ: OnKure Therapeutics, Inc., formerly Reneo Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure-based drug design platform, the Company is building a robust pipeline of tumor-agnostic candidates. The Company is developing OKI-219, a selective PI3KH1047R inhibitor, as its lead program. OKI-219 is being evaluated in a Phase I clinical trial in solid tumor patients with PI3KH1047R mutations, including breast cancer. The Company is also focused on targeting oncogenic PI3K and has multiple programs designed to enable targeting of this key oncogene.

2026-07-02 12:00

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

2026-06-24 23:29

Saccomano Nicholas A 🔴 sold 86 shares of OnKure Therapeutics, Inc. (OKUR) at $4.40 Transaction Date: Jun 22, 2026 | Filing ID: 000003

2026-06-24 23:27

Leverone Jason A. 🔴 sold 303 shares of OnKure Therapeutics, Inc. (OKUR) at $4.40 Transaction Date: Jun 22, 2026 | Filing ID: 000003

2026-06-08 22:32

Mathers Edward T 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 262279

2026-06-08 22:27

Ratcliffe Liam 🟢 acquired 1.3K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000004

2026-06-08 22:26

Phillips Andrew John 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000002

2026-06-08 22:25

Jansen Valerie Malyvanh 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000001

2026-06-08 22:24

GREY MICHAEL G 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000003

2026-06-08 22:23

Carruthers R Michael 🟢 acquired 7.7K shares (1 derivative) of OnKure Therapeutics, Inc. (OKUR) at $4.30 Transaction Date: Jun 04, 2026 | Filing ID: 000001

2026-06-05 17:16

New Form S-8 - OnKure Therapeutics, Inc. Filed: 2026-06-05 AccNo: 0001193125-26-259599 Size: 478 KB

No clinical trials found for this company.

No clinical products found for this company.